Eversense 365 is said to be the world's first one-year CGM system, offering a new long-term solution for diabetes management.

Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

Senseonics Holdings Inc (SENS) stock saw a decline, ending the day at $0.41 which represents a decrease of $-0.03 or -6.82% from the prior close of $0.44. The stock opened at $0.49 and touched a low ...

After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...

GERMANTOWN, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term ...

Senseonics Holdings Inc (SENS) stock saw a modest uptick, ending the day at $0.34 which represents a slight increase of $0.02 or 6.25% from the prior close of $0.32. The stock opened at $0.33 and ...

Senseonics and Ascensia Diabetes Care have announced that the U.S. Food and Drug Administration has cleared the next-generation Eversense 365 CGM, the first one-year CGM system ...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of ...

Analysts at StockNews.com started coverage on shares of Senseonics (NYSE:SENS – Get Free Report) in a research report issued to clients and investors on Wednesday. The brokerage set a “sell ...

The FDA has cleared Senseonics and Ascensia Diabetes Care's Eversense 365 Glucose Monitoring System. This system is designed for Type 1 and Type 2 diabetics 18 and older and will be the first ...

Senseonics Holdings, Inc. (NYSE: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...